An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...

That’s the simple thing Sorridimi’s going for: flavour, and fast. The man’s also behind Blackwood, the cafes in Cronulla and Bondi, and has teamed up with chef Joel Bennetts for his latest. Sana ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants. "Treatment-resistant depression can be very complicated, ...